Effect of sildenafil citrate on the cardiovascular system

Sildenafil citrate is a drug commonly used to manage erectile dysfunction. It is designated chemically as 1-[[3-(6,7-dihydro-1-methyl-7-oxo-3-propyl-1H-pyrazolo[4,3-d]pyrimidin- 5-yl)-4 ethoxyphenyl] sulfonyl]-4-methylpiperazine citrate (C22H30N6O4S). It is a highly selective inhibitor of cyclic gua...

Full description

Saved in:
Bibliographic Details
Main Authors: Shinlapawittayatorn K., Chattipakorn S., Chattipakorn N.
Format: Review
Language:English
Published: 2014
Online Access:http://www.scopus.com/inward/record.url?eid=2-s2.0-24744445028&partnerID=40&md5=69349dcddafa7050b84fbaed4273a4ad
http://www.ncbi.nlm.nih.gov/pubmed/16138212
http://cmuir.cmu.ac.th/handle/6653943832/1851
Tags: Add Tag
No Tags, Be the first to tag this record!
Institution: Chiang Mai University
Language: English
id th-cmuir.6653943832-1851
record_format dspace
spelling th-cmuir.6653943832-18512014-08-30T02:00:11Z Effect of sildenafil citrate on the cardiovascular system Shinlapawittayatorn K. Chattipakorn S. Chattipakorn N. Sildenafil citrate is a drug commonly used to manage erectile dysfunction. It is designated chemically as 1-[[3-(6,7-dihydro-1-methyl-7-oxo-3-propyl-1H-pyrazolo[4,3-d]pyrimidin- 5-yl)-4 ethoxyphenyl] sulfonyl]-4-methylpiperazine citrate (C22H30N6O4S). It is a highly selective inhibitor of cyclic guanine monophosphate-specific phosphodiesterase type 5. In late March through mid-November 1998, the US Food and Drug Administration (FDA) published a report on 130 confirmed deaths among men (mean age, 64 years) who received prescriptions for sildenafil citrate, a period during which >6 million outpatient prescriptions (representing about 50 million tablets) were dispensed. The US FDA recently reported that significant cardiovascular events, including sudden cardiac death, have occurred in men with erectile dysfunction who were taking sildenafil citrate. These reports have raised concerns that sildenafil citrate may increase the risk of cardiovascular events, particularly fatal arrhythmias, in patients with cardiovascular disease. In the past few years, the cardiac electrophysiological effects of sildenafil citrate have been investigated extensively in both animal and clinical studies. According to extensive data available to date, sildenafil citrate has been shown to pose minimal cardiovascular risks to healthy people taking this drug. Some precautions are needed for patients with cardiovascular diseases. However, the only absolute contraindication for sildenafil citrate is the concurrent use of nitrates. This article is intended to review sildenafil citrate's cardiovascular effects, as well as current debates about its arrhythmogenic effects. 2014-08-30T02:00:11Z 2014-08-30T02:00:11Z 2005 Review 0100879X 16138212 RBPMB http://www.scopus.com/inward/record.url?eid=2-s2.0-24744445028&partnerID=40&md5=69349dcddafa7050b84fbaed4273a4ad http://www.ncbi.nlm.nih.gov/pubmed/16138212 http://cmuir.cmu.ac.th/handle/6653943832/1851 English
institution Chiang Mai University
building Chiang Mai University Library
country Thailand
collection CMU Intellectual Repository
language English
description Sildenafil citrate is a drug commonly used to manage erectile dysfunction. It is designated chemically as 1-[[3-(6,7-dihydro-1-methyl-7-oxo-3-propyl-1H-pyrazolo[4,3-d]pyrimidin- 5-yl)-4 ethoxyphenyl] sulfonyl]-4-methylpiperazine citrate (C22H30N6O4S). It is a highly selective inhibitor of cyclic guanine monophosphate-specific phosphodiesterase type 5. In late March through mid-November 1998, the US Food and Drug Administration (FDA) published a report on 130 confirmed deaths among men (mean age, 64 years) who received prescriptions for sildenafil citrate, a period during which >6 million outpatient prescriptions (representing about 50 million tablets) were dispensed. The US FDA recently reported that significant cardiovascular events, including sudden cardiac death, have occurred in men with erectile dysfunction who were taking sildenafil citrate. These reports have raised concerns that sildenafil citrate may increase the risk of cardiovascular events, particularly fatal arrhythmias, in patients with cardiovascular disease. In the past few years, the cardiac electrophysiological effects of sildenafil citrate have been investigated extensively in both animal and clinical studies. According to extensive data available to date, sildenafil citrate has been shown to pose minimal cardiovascular risks to healthy people taking this drug. Some precautions are needed for patients with cardiovascular diseases. However, the only absolute contraindication for sildenafil citrate is the concurrent use of nitrates. This article is intended to review sildenafil citrate's cardiovascular effects, as well as current debates about its arrhythmogenic effects.
format Review
author Shinlapawittayatorn K.
Chattipakorn S.
Chattipakorn N.
spellingShingle Shinlapawittayatorn K.
Chattipakorn S.
Chattipakorn N.
Effect of sildenafil citrate on the cardiovascular system
author_facet Shinlapawittayatorn K.
Chattipakorn S.
Chattipakorn N.
author_sort Shinlapawittayatorn K.
title Effect of sildenafil citrate on the cardiovascular system
title_short Effect of sildenafil citrate on the cardiovascular system
title_full Effect of sildenafil citrate on the cardiovascular system
title_fullStr Effect of sildenafil citrate on the cardiovascular system
title_full_unstemmed Effect of sildenafil citrate on the cardiovascular system
title_sort effect of sildenafil citrate on the cardiovascular system
publishDate 2014
url http://www.scopus.com/inward/record.url?eid=2-s2.0-24744445028&partnerID=40&md5=69349dcddafa7050b84fbaed4273a4ad
http://www.ncbi.nlm.nih.gov/pubmed/16138212
http://cmuir.cmu.ac.th/handle/6653943832/1851
_version_ 1681419747751624704